Statins Tied to Lower Death Risk After Breakthrough Stroke

TOPLINEAmong patients with atrial fibrillation (AF) who experienced an ischaemic stroke (IS) while on oral anticoagulants, statin therapy at discharge was significantly associated with a lower risk for all‑cause mortality within 90 days of the stroke, without a significant increase in the risk for short‑term bleeding.METHODOLOGYResearchers conducted a real-world, multicentre, observational study using data from a registry of patients with AF who had an IS despite ongoing oral anticoagulation to assess whether statin therapy at hospital discharge was associated with 90-day all-cause mortality.They analysed 1442 patients with AF (mean age, 78.0 years; 48.3% men) who were hospitalised for IS while on continuous oral anticoagulant therapy between 2020 and 2025 and were discharged alive; of these, 1016 initiated statin therapy at discharge and 426 did not.Statin exposure was defined on the basis of prescription status at hospital discharge, whether therapy was newly initiated or continued from before admission; prescribing was left to the treating physicians' discretion.The primary outcome was all-cause mortality reported within 90 days of the index stroke (the first breakthrough IS) and after discharge; secondary outcomes were a composite vascular outcome (defined as recurrent IS, transient ischaemic attack [TIA], or vascular death) and recurrent IS or TIA.Safety outcomes were moderate-to-severe bleeding and intracranial haemorrhage (ICH).TAKEAWAYStatin therapy at discharge was associated with a 45% lower risk for all-cause mortality within 90 days of the index stroke (weighted hazard ratio [HR], 0.55; P < .001).Statin use showed a borderline association with a lower risk for the composite vascular outcome (HR, 0.63; P = .050). No significant association was observed for recurrent IS or TIA.Moderate-to-severe bleeding and ICH were rare and did not differ significantly between statin and non-statin groups.Among patients who restarted anticoagulation or had left atrial appendage closure, statin use was associated with a lower risk for mortality (HR, 0.53; 95% CI, 0.29-0.98).IN PRACTICE"[The study] findings should be regarded as hypothesis-generating; they provide preliminary effect-size estimates across clinically relevant subgroups that may inform the design and sample-size calculation of future randomized trials of statin therapy after breakthrough IS," the authors wrote.SOURCEThis study was led by Giovanni Merlino, MD, PhD, Department of Head, Neck and Neurosciences, Udine University Hospital, Udine, Italy. It was published online on November 03, 2026, in Therapeutic Advances in Neurological Disorders.LIMITATIONSThe retrospective design may have introduced residual confounding and prevented causal inferences. About 50% of the patients lacked lipid measurements, preventing the assessment of target lipid control and making it difficult to separate the effects of statins from those of lipid-lowering agents. The study lacked data on statin type, dose, adherence, and intensity.DISCLOSURESThis study did not receive any funding from any sources. Several authors declared receiving speaker fees, consultancy fees, advisory board fees, and/or other compensation from multiple pharmaceutical companies.This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.